European Group for Bone and Marrow Transplantation (EBMT)

Outcomes in patients treated with LentiGlobin for sickle cell disease (SCD ) gene therapy: Updated results from the phase 1 /2 HGB-206 Group C Study.

Authors: Mapara MY.